Welcome to our dedicated page for Acumen Pharmaceuticals SEC filings (Ticker: ABOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acumen Pharmaceuticals, Inc. filings document a clinical-stage biopharmaceutical issuer focused on Alzheimer’s disease programs targeting toxic soluble amyloid beta oligomers. Its Form 8-K reports include operating and financial results, business highlights, Regulation FD presentation updates, clinical and nonclinical program disclosures, and material agreements related to Enhanced Brain Delivery development.
Proxy materials describe annual meeting voting matters, board elections, auditor ratification, and equity incentive plan approvals. The filing record also discloses ABOS common stock registered on the Nasdaq Global Select Market, emerging growth company status, governance changes, capital-structure matters, and clinical and regulatory disclosure categories tied to drug development.
Acumen Pharmaceuticals (ABOS) reported a Form 4 showing a director received a stock option grant for 50,000 shares on 11/06/2025 at an exercise price of $1.9 per share. The option expires 11/06/2035.
The award vests in equal monthly installments over three years, becoming fully vested on the third anniversary of the grant date, and will become immediately exercisable prior to the effectiveness of a change in control. Following the reported transaction, 50,000 derivative securities were beneficially owned, held directly.
Acumen Pharmaceuticals (ABOS) filed a Form 3, the initial statement of beneficial ownership under Section 16. The filing identifies the reporting person as a Director and indicates it was filed by one reporting person. The Form 3 states that no securities are beneficially owned. The date of the event requiring the statement is 11/06/2025. A Power of Attorney is included as Exhibit 24.1, and the form is signed by attorney-in-fact Derek Meisner.
Acumen Pharmaceuticals (ABOS) appointed Dr. George Golumbeski to its Board and as Chairman, effective November 6, 2025. He will serve as a Class II director until the 2026 annual meeting and was deemed independent under Nasdaq rules, replacing Dr. Sean Stalfort as Chairman.
Under the company’s director compensation policy, he received an initial option for 50,000 shares at the closing price on the grant date, with a 10-year term vesting monthly over three years. He will receive a $40,000 annual Board retainer and a $30,000 annual Chairman retainer. The company entered into its standard director indemnification agreement with him, and disclosed no related-party arrangements.
Acumen Pharmaceuticals (ABOS) is reported to have a combined 3,417,075 shares beneficially owned by Sands-linked reporting persons, representing 5.6% of the outstanding common stock based on 60,573,425 shares. The position is held across three Sands funds—Sands Capital Ventures Discovery Fund III (1,124,729 shares, 1.9%), Sands Capital Global Venture Fund II (1,146,173 shares, 1.9%) and Sands Capital Life Sciences Pulse Fund (1,146,173 shares, 1.9%)—with Sands Capital Alternatives acting as investment manager and Frank M. Sands retaining ultimate voting and investment power. The filing reports shared voting and dispositive power rather than sole control and includes a certification that the securities were not acquired to influence control.
Acumen Pharmaceuticals (ABOS) is a clinical-stage company advancing sabirnetug, an oligomer-targeted monoclonal antibody for Alzheimer’s disease. The company completed enrollment in its Phase 2 ALTITUDE-AD trial in March 2025 after initiating dosing in May 2024, and its Phase 1 INTERCEPT-AD topline results met primary and secondary objectives in July 2023. As of June 30, 2025, Acumen held $166.2 million of cash and marketable securities and reported working capital of $123.5 million, which management believes funds operations into early 2027.
Operating results reflect rapidly higher development spending: research and development expense rose to $62.4 million for the six months ended June 30, 2025 (up 95% year-over-year), driving a net loss of $69.7 million for the same period and an accumulated deficit of $394.9 million. The company has a $31.6 million term loan with embedded derivatives and an effective interest rate around 14% for the period. In July 2025 Acumen entered a collaboration with JCR with potential payments and milestones up to $555 million plus royalties.
Acumen Pharmaceuticals reported that it has furnished an earnings press release and posted an updated investor presentation that reflects the companys cash, cash equivalents and marketable securities balance as of June 30, 2025. The filing states these materials are furnished as Exhibits 99.1 and 99.2 and explicitly notes that the furnished information is not being "filed" under the Exchange Act and is not incorporated by reference in other securities filings.
The Form 8-K does not include numeric financial results within the filing itself; instead it directs readers to the furnished press release and presentation for details. The company also states that the submission is not an admission as to materiality of any Regulation FD disclosures.